Rabeprazole

Baldwin, Claudine M; Keam, Susan J.

doi:10.2165/00003495-200969100-00007

Cited by 25 publications

(14 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Both H 2 blockers and PPIs can control acid hypersecretion in all patients who can take oral medications and are cooperative [2,8,32,57,172,173]. The preferred drugs are now PPIs, because of their long duration of action [8,32,57,172,174,175,176,177,178]. H 2 blockers to be effective are usually required at higher doses than used in conventional peptic disease (frequently up to 10 times the usual dose) and 4-6 h dosing is frequent [2,3,57,75].…”

Section: Medical Treatment Of Functional P-nets [125813141557mentioning

confidence: 99%

“…PPIs are the drugs of choice because of their long duration of action allowing once or twice a day dosing in most patients. Studies show all available PPIs (omeprazole, lansoprazole, pantoprazole, rabeprezole, esomeprazole) are effective [8,32,57,172,174,175,176,177,178]. The recommended starting dose is equivalent to omeprazole 60 mg once per day in sporadic ZES and 40-60 mg b.i.d.…”

Section: Medical Treatment Of Functional P-nets [125813141557mentioning

confidence: 99%

See 1 more Smart Citation

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

Jensen¹,

et al. 2012

View full text Add to dashboard Cite

Section: Medical Treatment Of Functional P-nets [125813141557mentioning

confidence: 99%

Section: Medical Treatment Of Functional P-nets [125813141557mentioning

confidence: 99%

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

Jensen¹,

et al. 2012

View full text Add to dashboard Cite

“…While many studies suggest this to be true regardless of the PPI used, some reports have suggested that the therapeutic outcomes are less influenced by genotype in PPIs with less dependence on CYP2C19 metabolism, namely rabeprazole and esomeprazole [71,73,80]. Nonetheless, other studies suggest CYP2C19 is important for all PPIs.…”

Section: Cyp2c19 and Ppi Pharmacogeneticsmentioning

confidence: 99%

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Rouby

Lima

Johnson

2018

Expert Opinion on Drug Metabolism & Toxicology

190

172

View full text Add to dashboard Cite

Introduction: Proton Pump inhibitors (PPIs) are commonly used for a variety of acid related disorders. Despite the overall effectiveness and safety profile of PPIs, some patients do not respond adequately or develop treatment related adverse events. This variable response among patients is in part due to genotype variability of CYP2C19, the gene encoding the CYP450 (CYP2C19) isoenzyme responsible for PPIs metabolism.Areas covered: This article provides an overview of the pharmacokinetics and mechanism of action of the currently available PPIs, including the magnitude of CYPC19 contribution to their metabolism. Additionally, the role of CYP2C19 genetic variability in the therapeutic effectiveness or outcomes of PPI therapy is highlighted in details, to provide supporting evidence for the potential value of CYP2C19 genotype-guided approaches to PPI drug therapy.Expert opinion: There is a large body of evidence describing the impact of CYP2C19 variability on PPIs and its potential role in individualizing PPI therapy, yet, CYP2C19 pharmacogenetics has not been widely implemented into clinical practice. More data are needed but CYP2C19 genotype-guided dosing of PPIs is likely to become increasingly common and is expected to improve clinical outcomes, and minimize side effects related to PPIs.

show abstract

“…Rabeprazole is less susceptible to the influence of genetic polymorphisms for CYP2C19. Thus, it has greater and faster acid suppression compared to older PPIs [25]. Amoxicillin is one of the effective antibiotics to H. pylori with few side effects.…”

Section: Introductionmentioning

confidence: 99%

Functional and Molecular Surveillance of Helicobacter pylori Antibiotic Resistance in Kuala Lumpur

et al. 2014

View full text Add to dashboard Cite

Background Helicobacter pylori is the etiological agent for diseases ranging from chronic gastritis and peptic ulcer disease to gastric adenocarcinoma and primary gastric B-cell lymphoma. Emergence of resistance to antibiotics possesses a challenge to the effort to eradicate H. pylori using conventional antibiotic-based therapies. The molecular mechanisms that contribute to the resistance of these strains have yet to be identified and are important for understanding the evolutional pattern and selective pressure imposed by the environment.Methods and Findings H. pylori was isolated from 102 patients diagnosed with gastrointestinal diseases, who underwent endoscopy at University Malaya Medical Centre (UMMC). The isolates were tested for their susceptibility on eleven antibiotics using Etest. Based on susceptibility test, 32.3% of the isolates were found to have primary metronidazole resistance; followed by clarithromycin (6.8%) and fluoroquinolones (6.8%). To further investigate the resistant strains, mutational patterns of gene rdxA, frxA, gyrA, gyrB, and 23S rRNA were studied. Consistent with the previous reports, metronidazole resistance was prevalent in the local population. However, clarithromycin, fluoroquinolone and multi-drug resistance were shown to be emerging. Molecular patterns correlated well with phenotypic data. Interestingly, multi-drug resistant (MDR) strains were found to be associated with higher minimum inhibitory concentration (MIC) than their single-drug resistant (SDR) counterparts. Most importantly, clarithromycin-resistant strains were suggested to have a higher incidence for developing multi-drug resistance.ConclusionData from this study highlighted the urgency to monitor closely the prevalence of antibiotic resistance in the Malaysian population; especially that of clarithromycin and multi-drug resistance. Further study is needed to understand the molecular association between clarithromycin resistance and multi-drug resistance in H. pylori. The report serves a reminder that a strict antibiotic usage policy is needed in Malaysia and other developing countries (especially those where H. pylori prevalence remained high).

show abstract

Rabeprazole

Cited by 25 publications

References 81 publications

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms: Functional Pancreatic Endocrine Tumor Syndromes

Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine

Functional and Molecular Surveillance of Helicobacter pylori Antibiotic Resistance in Kuala Lumpur

Contact Info

Product

Resources

About